Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Fajac

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2023
AQP5, a second gene at play with CFTR in aquagenic palmoplantar keratodermaBrian Sperelakis-Beedham, Maureen Lopez, Emmanuelle Bourrat, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
Annals of the American Thoracic Society|March 16, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension studyJames F Chmiel, Kimberly McBennett, Bradley S Quon, et al.
The European Respiratory Journal|January 19, 2024
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare <i>CFTR</i> variants: a viewpointPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
The European Respiratory Journal|June 12, 2025
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trialBarry J Plant, Gisli G Einarsson, Kevin F Deasy, et al.
The Lancet. Respiratory Medicine|May 20, 2014
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialEitan Kerem, Michael W Konstan, Kris De Boeck, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspectiveNicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, et al.
The Lancet. Respiratory Medicine|October 2, 2019
The future of cystic fibrosis care: a global perspectiveScott C Bell, Marcus A Mall, Hector Gutierrez, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 21, 2023
Standards for the care of people with cystic fibrosis; establishing and maintaining healthKevin W Southern, Charlotte Addy, Scott C Bell, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2023
AQP5, a second gene at play with CFTR in aquagenic palmoplantar keratodermaBrian Sperelakis-Beedham, Maureen Lopez, Emmanuelle Bourrat, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
Annals of the American Thoracic Society|March 16, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension studyJames F Chmiel, Kimberly McBennett, Bradley S Quon, et al.
The European Respiratory Journal|January 19, 2024
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare <i>CFTR</i> variants: a viewpointPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
The European Respiratory Journal|June 12, 2025
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trialBarry J Plant, Gisli G Einarsson, Kevin F Deasy, et al.
The Lancet. Respiratory Medicine|May 20, 2014
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialEitan Kerem, Michael W Konstan, Kris De Boeck, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspectiveNicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, et al.
The Lancet. Respiratory Medicine|October 2, 2019
The future of cystic fibrosis care: a global perspectiveScott C Bell, Marcus A Mall, Hector Gutierrez, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 21, 2023
Standards for the care of people with cystic fibrosis; establishing and maintaining healthKevin W Southern, Charlotte Addy, Scott C Bell, et al.
Pageof 8